Evaluating the clinical impact of the 2023 FIGO staging for endometrial cancer: Complexities and considerations.

We wish to direct your attention to the recent update of the FIGO staging for endometrial cancer, as elucidated by the works of Berek et al. [ [1] Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N; Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee. FIGO staging of endometrial cancer: 2023. J Gynecol Oncol. 2023 Sep;34(5):e85. doi: 10.3802/jgo.2023.34.e85. Epub 2023 Aug 8. PMID: 37593813; PMCID: PMC10482588. Google Scholar ]. This revised framework introduces several noteworthy alterations to the preceding FIGO staging paradigm. It is of paramount importance for us to undertake a rigorous examination of these modifications to fully apprehend their ramifications for both clinical practice and research. With the introduction of precise histopathological criteria, one should consider that the novel classification is far more complex, bringing the question of its reproducibility in clinical routine practice.